Skip to content Skip to footer
VIEWPOINTS_Curtis Rambaran_2023

Curtis Rambaran’s Insights from Zerlasiran P-II Study for Patients with Elevated Lipoprotein (a) at High-Risk ASCVD Events

Shots:Curtis gave a brief introduction about Zerlasiran. He also talked about the study design and the results from the P-II trial (ALPACAR-360) under which Zerlasiran is being evaluatedHe also highlighted how Zerlasiran can differ from other therapies that are in development to treat elevated lipoprotein (a) at high risk of atherosclerotic cardiovascular disease (ASCVD)…

Read more

RNAi Therapeutic Top 20 2022

Top 20 RNAi Therapeutic Companies Based on 2022 R&D Expenditure

Shots:RNAi Therapeutic leverages the biological response of degrading (mRNA) before it gets translated into a protein. By using short double-stranded RNA in silencing a targeted disease-causing mutation, researchers are working steadfastly in multiple indications to expand RNAi therapeuticRNAi therapy comes to the rescue when targeting a specific protein gets difficult using a conventional…

Read more

Sign Up to Our Newsletter

Be the first to know the latest updates

[mc4wp_form id="13387" element_id="style-1"]